The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer
Introduction: Carboplatin is an anticancer drug used for treatment of various types of cancer including non-small cell lung cancer (NSCLC). Dosing is based on estimated glomerular filtration rate (GFR) using the Cockcroft-Gault formula. In overweight patients, the GFR is more likely overestimated, r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222001678 |
| _version_ | 1811176483177103360 |
|---|---|
| author | M.P. Kicken H.D. Kilinc C.M. Cramer-van der Welle S. Houterman B.E.E.M. van den Borne A.A.J. Smit E.M.W. van de Garde M.J. Deenen |
| author_facet | M.P. Kicken H.D. Kilinc C.M. Cramer-van der Welle S. Houterman B.E.E.M. van den Borne A.A.J. Smit E.M.W. van de Garde M.J. Deenen |
| author_sort | M.P. Kicken |
| collection | DOAJ |
| description | Introduction: Carboplatin is an anticancer drug used for treatment of various types of cancer including non-small cell lung cancer (NSCLC). Dosing is based on estimated glomerular filtration rate (GFR) using the Cockcroft-Gault formula. In overweight patients, the GFR is more likely overestimated, resulting in a potentially overdose of carboplatin affecting treatment response. This study investigated the association of body mass index (BMI) on overall survival (OS) and progression-free survival (PFS) in stage-IV NSCLC patients treated with first-line carboplatin-based chemotherapy. Secondary safety endpoints were thrombocytopenia and toxicity-related hospitalizations. Materials and methods: This was a retrospective multicenter cohort study. Patients were categorized according to BMI<25.0 kg/m2 (normal weight and reference), 25.0-29.9 kg/m2 (overweight) or ≥30.0 kg/m2 (obese). For survival analyses adjusted hazard ratios [aHR] were calculated using multivariate Cox regression analysis. Secondary outcomes were analyzed using multivariate logistic regression providing adjusted odd ratios [aOR]. Results: Overweight patients (n=174) had a significantly better OS (aHR=0.72, 95%-CI:0.59-0.89) and PFS (aHR=0.74, 95%-CI:0.61-0.90) compared to normal weight patients (n=268). OS nor PFS were different in obese (n=51) compared to normal weight patients. However, obesity was associated with significantly higher incidences of thrombocytopenia grade ≥3 (aOR=3.47, 95%-CI:1.75-6.90). Conclusion: This study shows a significantly longer survival for overweight compared to normal weight patients. Obese patients have an increased risk for grade ≥3 thrombocytopenia without a difference in survival following carboplatin-based chemotherapy. The implications for clinical practice are to use the Cockcroft-Gault formula with caution in patients with BMI≥30.0 kg/m2, and to verify calculated dosing of carboplatin for appropriateness. |
| first_indexed | 2024-04-10T19:52:20Z |
| format | Article |
| id | doaj.art-f9bd66ceb6a641ff899150515f489eec |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-04-10T19:52:20Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-f9bd66ceb6a641ff899150515f489eec2023-01-28T04:08:08ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0134100676The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancerM.P. Kicken0H.D. Kilinc1C.M. Cramer-van der Welle2S. Houterman3B.E.E.M. van den Borne4A.A.J. Smit5E.M.W. van de Garde6M.J. Deenen7Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Clinical Pharmacy, Catharina Hospital, Eindhoven, The NetherlandsSanteon Hospital Group, Utrecht, The NetherlandsDepartment of Education and Research, Catharina Hospital, The NetherlandsDepartment of Pulmonology, Catharina Hospital, The NetherlandsDepartment of Pulmonary Medicine, OLVG Hospital, The NetherlandsDepartment of Clinical Pharmacy, St. Antonius Hospital, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, The NetherlandsDepartment of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The NetherlandsIntroduction: Carboplatin is an anticancer drug used for treatment of various types of cancer including non-small cell lung cancer (NSCLC). Dosing is based on estimated glomerular filtration rate (GFR) using the Cockcroft-Gault formula. In overweight patients, the GFR is more likely overestimated, resulting in a potentially overdose of carboplatin affecting treatment response. This study investigated the association of body mass index (BMI) on overall survival (OS) and progression-free survival (PFS) in stage-IV NSCLC patients treated with first-line carboplatin-based chemotherapy. Secondary safety endpoints were thrombocytopenia and toxicity-related hospitalizations. Materials and methods: This was a retrospective multicenter cohort study. Patients were categorized according to BMI<25.0 kg/m2 (normal weight and reference), 25.0-29.9 kg/m2 (overweight) or ≥30.0 kg/m2 (obese). For survival analyses adjusted hazard ratios [aHR] were calculated using multivariate Cox regression analysis. Secondary outcomes were analyzed using multivariate logistic regression providing adjusted odd ratios [aOR]. Results: Overweight patients (n=174) had a significantly better OS (aHR=0.72, 95%-CI:0.59-0.89) and PFS (aHR=0.74, 95%-CI:0.61-0.90) compared to normal weight patients (n=268). OS nor PFS were different in obese (n=51) compared to normal weight patients. However, obesity was associated with significantly higher incidences of thrombocytopenia grade ≥3 (aOR=3.47, 95%-CI:1.75-6.90). Conclusion: This study shows a significantly longer survival for overweight compared to normal weight patients. Obese patients have an increased risk for grade ≥3 thrombocytopenia without a difference in survival following carboplatin-based chemotherapy. The implications for clinical practice are to use the Cockcroft-Gault formula with caution in patients with BMI≥30.0 kg/m2, and to verify calculated dosing of carboplatin for appropriateness.http://www.sciencedirect.com/science/article/pii/S2468294222001678OverweightBMINSCLCOverdosingToxicitySurvival |
| spellingShingle | M.P. Kicken H.D. Kilinc C.M. Cramer-van der Welle S. Houterman B.E.E.M. van den Borne A.A.J. Smit E.M.W. van de Garde M.J. Deenen The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer Cancer Treatment and Research Communications Overweight BMI NSCLC Overdosing Toxicity Survival |
| title | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer |
| title_full | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer |
| title_fullStr | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer |
| title_full_unstemmed | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer |
| title_short | The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer |
| title_sort | association of body mass index with safety and effectiveness of first line carboplatin based chemotherapy in patients with metastatic non small cell lung cancer |
| topic | Overweight BMI NSCLC Overdosing Toxicity Survival |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222001678 |
| work_keys_str_mv | AT mpkicken theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT hdkilinc theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT cmcramervanderwelle theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT shouterman theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT beemvandenborne theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT aajsmit theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT emwvandegarde theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT mjdeenen theassociationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT mpkicken associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT hdkilinc associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT cmcramervanderwelle associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT shouterman associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT beemvandenborne associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT aajsmit associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT emwvandegarde associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer AT mjdeenen associationofbodymassindexwithsafetyandeffectivenessoffirstlinecarboplatinbasedchemotherapyinpatientswithmetastaticnonsmallcelllungcancer |